New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
15:54 EDTPCYC, GSK, JNJPharmacyclics announces trial results of Imbruvica vs. ofatumumab
Pharmacyclics (PCYC) announced trial results of the first Phase III study, RESONATE, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA, ibrutinib, versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL. Patients receiving IMBRUVICA realized a significant improvement in progression free survival, PFS, overall survival, OS, and overall response rate, ORR, as compared to patients receiving ofatumumab (GSK). The RESONATE data will be discussed in the official Press Program by lead investigator Dr. John Byrd from The Ohio State University Medical Center at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. This release corresponds to abstract LBA7008. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
News For PCYC;GSK;JNJ From The Last 14 Days
Check below for free stories on PCYC;GSK;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
09:16 EDTJNJOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTJNJOrganovo enters 3D bio-printed tissue agreement with J&J unit
Organovo (ONVO) announced that it has entered into an agreement with Janssen Research and Development, a pharmaceutical company of Johnson & Johnson (JNJ), to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the company’s work in 3D liver tissue for toxicity testing. Terms were not disclosed.
08:19 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
06:13 EDTGSKGlaxoSmithKline's malaria vaccine candidate accepted for EU regulatory review
Subscribe for More Information
July 23, 2014
14:32 EDTPCYCPharmacyclics estimates raised ahead of Q2 report at Goldman
Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data. The firm rates shares a Buy with a $162 price target.
09:33 EDTGSKGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
09:17 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:19 EDTGSKGenmab reports Q2 Arzerra net sales GBP 12.8M
Subscribe for More Information
07:12 EDTGSKGlaxoSmithKline lowers 2014 core EPS outlook to 'similar' to 2013
GSK now expects 2014 core EPS to be "broadly similar" to 2013 versus previous expectations of 4%-8% growth. It added, "Given impact of recent sustained strength of Sterling on free cash flow, share repurchases over balance of 2014 likely to be immaterial."
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information
07:09 EDTGSKMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
July 22, 2014
09:55 EDTGSKLupin, private equity funds weigh bids for GSK's older drugs, Reuters reports
Subscribe for More Information
July 21, 2014
18:40 EDTJNJOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
17:03 EDTJNJJohnson & Johnson announces $5B share repurchase program
Johnson & Johnson announced that its board has approved the repurchase of up to $5B of the company's common stock. The company had approximately 2.82B shares of common stock outstanding as of June 29.
17:01 EDTJNJJohnson & Johnson announces $5B share repurchase program
07:11 EDTGSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 17, 2014
14:54 EDTJNJJohnson & Johnson weakness creates buying opportunity, says Argus
Subscribe for More Information
10:56 EDTJNJJohnson & Johnson reports 18% passive stake in Minerva
Subscribe for More Information
07:18 EDTGSKMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
06:23 EDTGSKGlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use